CH02 peptide promotes ex vivo                     expansion of umbilical cord blood-derived CD34<sup>+</sup> hematopoietic                     stem/progenitor cells

Yang Yiqi; Zhang Bihui; Xie Junye; Li Jingsheng; Liu Jia; Liu Rongzhan; Zhang Linhao; Zhang Jinting; Su Zijian; Li Fu; Zhang Leisheng; Hong An; Chen Xiaojia

doi:10.3724/abbs.2023047

Acta Biochimica et Biophysica Sinica (Jun 2023)

CH02 peptide promotes ex vivo expansion of umbilical cord blood-derived CD34<sup>+</sup> hematopoietic stem/progenitor cells

Yang Yiqi,
Zhang Bihui,
Xie Junye,
Li Jingsheng,
Liu Jia,
Liu Rongzhan,
Zhang Linhao,
Zhang Jinting,
Su Zijian,
Li Fu,
Zhang Leisheng,
Hong An,
Chen Xiaojia

Affiliations

Yang Yiqi: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China","The First Affiliated Hospital, Ji’nan University, Guangzhou 510630, China"]
Zhang Bihui: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China"]
Xie Junye: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China"]
Li Jingsheng: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China"]
Liu Jia: ["The First Affiliated Hospital, Ji’nan University, Guangzhou 510630, China"]
Liu Rongzhan: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China"]
Zhang Linhao: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China"]
Zhang Jinting: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China"]
Su Zijian: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China"]
Li Fu: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China"]
Zhang Leisheng: ["Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province & NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou 730000, China","Key Laboratory of Radiation Technology and Biophysics, Hefei Institute of Physical Science, Chinese Academy of Sciences, Hefei 230031, China"]
Hong An: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China","The First Affiliated Hospital, Ji’nan University, Guangzhou 510630, China"]
Chen Xiaojia: ["Institute of Biomedicine & Department of Cell Biology, College of Life Science and Technology, Guangdong Province Key Laboratory of Bioengineering Medicine, Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center; National Engineering Research Center of Genetic Medicine, Ji’nan University, Guangzhou 510632, China","The First Affiliated Hospital, Ji’nan University, Guangzhou 510630, China"]

DOI: https://doi.org/10.3724/abbs.2023047
Journal volume & issue: Vol. 55
pp. 1630 – 1639

Abstract

Read online

Umbilical cord blood (UCB) is an advantageous source for hematopoietic stem/progenitor cell (HSPC) transplantation, yet the current strategies for large-scale and cost-effective UCB-HSPC preparation are still unavailable. To overcome these obstacles, we systematically evaluate the feasibility of our newly identified CH02 peptide for ex vivo expansion of CD34+ UCB-HSPCs. We herein report that the CH02 peptide is specifically enriched in HSPC proliferation via activating the FLT3 signaling. Notably, the CH02-based cocktails are adequate for boosting 12-fold ex vivo expansion of UCB-HSPCs. Meanwhile, CH02-preconditioned UCB-HSPCs manifest preferable efficacy upon wound healing in diabetic mice via bidirectional orchestration of proinflammatory and anti-inflammatory factors. Together, our data indicate the advantages of the CH02-based strategy for ex vivo expansion of CD34+ UCB-HSPCs, which will provide new strategies for further development of large-scale HSPC preparation for clinical purposes.

Published in Acta Biochimica et Biophysica Sinica

ISSN: 1672-9145 (Print); 1745-7270 (Online)
Publisher: China Science Publishing & Media Ltd.
Country of publisher: China
LCC subjects: Science: Chemistry: Organic chemistry: Biochemistry; Science: Biology (General): Genetics
Website: https://www.sciengine.com/ABBS/home

About the journal

Abstract

Keywords